Juan M. Irache

Prof. Juan M. Irache

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2008 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
Juan M. IracheJuan M. Irache
Juan M. Irache
HSHesham H Salman
Hesham H Salman
CGCarlos Gamazo
Carlos Gamazo
Socorro EspuelasSocorro Espuelas
Socorro Espuelas
Background: The specific targeting of nanomedicines to mannose receptors, highly expressed in cells of the immune system, performs a useful strategy for improving the efficacy of vaccines and chemotherapy. Objective: This review discusses the potential of mannose-targeted drug/antigen delivery systems for vaccination and treatment of diseases localized in macrophages and other antigen-presenting cells. Methods: The first part of the review describes the characteristics, localization and functions of mannose receptors. The following sections are devoted to the description of different methods used to deliver therapeutic agents, including mannose conjugates and mannosylated carriers or particulates (i.e., liposomes, nanoparticles and niosomes). Results/conclusions: A general overview of published reports confirms the effectiveness of mannosylation strategies, although the optimization and full exploitation of mannose-targeted drug delivery systems would require a deeper understanding of the structure–activi...

1 February 2015 in Food Hydrocolloids
Verified
Journal Article
Closed access
RPRebeca Penalva
Rebeca Penalva
IEIrene Esparza
Irene Esparza
MAMaite Agüeros
Maite Agüeros
CGCarlos Javier González-Navarro
Carlos Javier González-Navarro
CGCarolina Gonzalez-Ferrero
Carolina Gonzalez-Ferrero
Juan M. IracheJuan M. Irache
Juan M. Irache

9 June 2015 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
RPRebeca Penalva
Rebeca Penalva
IEIrene Esparza
Irene Esparza
Eneko LarrañetaEneko Larrañeta
Eneko Larrañeta
CGCarlos Javier González-Navarro
Carlos Javier González-Navarro
CGCarlos Gamazo
Carlos Gamazo
Juan M. IracheJuan M. Irache
Juan M. Irache

1 January 2001 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
MMMarta Merodio
Marta Merodio
AAAmaia Arnedo
Amaia Arnedo
MRM.Jesús Renedo
M.Jesús Renedo
Juan M. IracheJuan M. Irache
Juan M. Irache

1 April 1996 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
IEIsabel Ezpeleta
Isabel Ezpeleta
Juan M. IracheJuan M. Irache
Juan M. Irache
SSSerge Stainmesse
Serge Stainmesse
CCChristiane Chabenat
Christiane Chabenat
JGJacques Gueguen
Jacques Gueguen
AOAnne-Marie Orecchioni
Anne-Marie Orecchioni

Verified
Journal Article
Open access
PDF file
RPRebeca Peñalva
Rebeca Peñalva
JMJorge Morales
Jorge Morales
CGCarlos Javier González-Navarro
Carlos Javier González-Navarro
Eneko LarrañetaEneko Larrañeta
Eneko Larrañeta
GQGemma Quincoces
Gemma Quincoces
Juan M. IracheJuan M. Irache
Juan M. Irache
Resveratrol is a naturally occurring polyphenol that provides several health benefits including cardioprotection and cancer prevention. However, its biological activity is limited by a poor bioavailability when taken orally. The aim of this work was to evaluate the capability of casein nanoparticles as oral carriers for resveratrol. Nanoparticles were prepared by a coacervation process, purified and dried by spray-drying. The mean size of nanoparticles was around 200 nm with a resveratrol payload close to 30 μg/mg nanoparticle. In vitro studies demonstrated that the resveratrol release from casein nanoparticles was not affected by the pH conditions and followed a zero-order kinetic. When nanoparticles were administered orally to rats, they remained within the gut, displaying an important capability to reach the intestinal epithelium. No evidence of nanoparticle “translocation” were observed. The resveratrol plasma levels were high and sustained for at least 8 h with a similar profile to that observed for the presence of the major metabolite in plasma. The oral bioavailability of resveratrol when loaded in casein nanoparticles was calculated to be 26.5%, 10 times higher than when the polyphenol was administered as oral solution. Finally, a good correlation between in vitro and in vivo data was observed.